Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?

References

1. 1.↵
   1. Cummings J,
   2. Apostolova L,
   3. Rabinovici GD, et al

   . Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 2023;10:362–77 doi:10.14283/jpad.2023.30 pmid:37357276

   CrossRefPubMed
2. 2.↵
   FDA approves treatment for adults with Alzheimer’s disease. US Food and Drug Administration. July 2, 2024; available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease
3. 3.↵
   1. Soderberg L,
   2. Johannesson M,
   3. Nygren P, et al

   . Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease. Neurotherapeutics 2023;20:195–206 doi:10.1007/s13311-022-01308-6 pmid:36253511

   CrossRefPubMed
4. 4.↵
   1. van Dyck CH,
   2. Swanson CJ,
   3. Aisen P, et al

   . Lecanemab in early Alzheimer’s disease. N Engl J Med 2023;388:9–21 doi:10.1056/NEJMoa2212948 pmid:36449413

   CrossRefPubMed
5. 5.↵
   1. Lee K,
   2. Mahmud M,
   3. Marx D, et al

   . Clinical arterial spin-labeling MR imaging to screen for typical and atypical neurodegenerative disease in the new era of Alzheimer treatment. AJNR Am J Neuroradiol 2024;45:632–36 doi:10.3174/ajnr.A8164 pmid:38485200

   Abstract/FREE Full Text
6. 6.↵
   1. Wierenga CE,
   2. Hays CC,
   3. Zlatar ZZ

   . Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer’s disease. J Alzheimers Dis 2014;42 Suppl 4:S411–19 doi:10.3233/JAD-141467 pmid:25159672

   CrossRefPubMed
7. 7.↵
   1. Wolk DA,
   2. Detre JA

   . Arterial spin labeling MRI: an emerging biomarker for Alzheimer’s disease and other neurodegenerative conditions. Curr Opin Neurol 2012;25:421–28 doi:10.1097/WCO.0b013e328354ff0a pmid:22610458

   CrossRefPubMed
8. 8.↵
   1. Zago W,
   2. Schroeter S,
   3. Guido T, et al

   . Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: implications for amyloid-related imaging abnormalities. Alzheimers Dement 2013;9:S105–15 doi:10.1016/j.jalz.2012.11.010 pmid:23583235

   CrossRefPubMed
9. 9.↵
   1. Uekawa K,
   2. Hattori Y,
   3. Ahn SJ, et al

   . Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress. Mol Neurodegener 2023;18:73 doi:10.1186/s13024-023-00660-1 pmid:37789345

   CrossRefPubMed
10. 10.↵
    1. Kakuda N,
    2. Miyasaka T,
    3. Iwasaki N, et al

    . Distinct deposition of amyloid-beta species in brains with Alzheimer’s disease pathology visualized with MALDI imaging mass spectrometry. Acta Neuropathol Commun 2017;5:73 doi:10.1186/s40478-017-0477-x pmid:29037261

    CrossRefPubMed
11. 11.↵
    1. Raz L,
    2. Knoefel J,
    3. Bhaskar K

    . The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab 2016;36:172–86 doi:10.1038/jcbfm.2015.164 pmid:26174330

    CrossRefPubMed
12. 12.↵
    1. Hanaoka T,
    2. Kimura N,
    3. Aso Y, et al

    . Relationship between white matter lesions and regional cerebral blood flow changes during longitudinal follow up in Alzheimer’s disease. Geriatr Gerontol Int 2016;16:836–42 doi:10.1111/ggi.12563 pmid:26245516

    CrossRefPubMed
13. 13.↵
    1. Weijs RWJ,
    2. Shkredova DA,
    3. Brekelmans ACM, et al

    . Longitudinal changes in cerebral blood flow and their relation with cognitive decline in patients with dementia: current knowledge and future directions. Alzheimers Dement 2023;19:532–48 doi:10.1002/alz.12666 pmid:35485906

    CrossRefPubMed
14. 14.↵
    1. Chen Y,
    2. Wolk DA,
    3. Reddin JS, et al

    . Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology 2011;77:1977–85 doi:10.1212/WNL.0b013e31823a0ef7 pmid:22094481

    CrossRefPubMed
15. 15.↵
    1. Morgan D

    . Mechanisms of Abeta plaque clearance following passive A beta immunization. Neurodegener Dis 2005;2:261–66 doi:10.1159/000090366 pmid:16909007

    CrossRefPubMed
16. 16.↵
    1. Qiao Y,
    2. Chi Y,
    3. Zhang Q, et al

    . Safety and efficacy of lecanemab for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. Front Aging Neurosci 2023;15:1169499 doi:10.3389/fnagi.2023.1169499 pmid:37213538

    CrossRefPubMed
17. 17.↵
    1. Chen ZL,
    2. Singh PK,
    3. Calvano M, et al

    . A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer’s disease. Proc Natl Acad Sci U S A 2023;120:e2309389120 doi:10.1073/pnas.2309389120 pmid:37639602

    CrossRefPubMed
18. 18.↵
    1. Shields LBE,
    2. Hust H,
    3. Cooley SD, et al

    . Initial experience with lecanemab and lessons learned in 71 patients in a regional medical center. J Prev Alzheimers Dis 2024;11:1549–62 doi:10.14283/jpad.2024.159 pmid:39559868

    CrossRefPubMed